Compare PRAX & NTNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | NTNX |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.9B |
| IPO Year | 2020 | 2015 |
| Metric | PRAX | NTNX |
|---|---|---|
| Price | $331.79 | $36.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 19 |
| Target Price | ★ $572.13 | $62.29 |
| AVG Volume (30 Days) | 345.8K | ★ 3.3M |
| Earning Date | 05-01-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 227.45 |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $2,537,927,000.00 |
| Revenue This Year | N/A | $13.60 |
| Revenue Next Year | $6,395.88 | $13.18 |
| P/E Ratio | ★ N/A | $60.30 |
| Revenue Growth | N/A | ★ 18.11 |
| 52 Week Low | $28.79 | $34.01 |
| 52 Week High | $354.87 | $83.36 |
| Indicator | PRAX | NTNX |
|---|---|---|
| Relative Strength Index (RSI) | 57.17 | 40.16 |
| Support Level | $282.49 | $35.84 |
| Resistance Level | $327.65 | $42.19 |
| Average True Range (ATR) | 17.60 | 1.97 |
| MACD | 2.86 | -0.31 |
| Stochastic Oscillator | 81.68 | 29.14 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.